152 related articles for article (PubMed ID: 34044732)
21. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
[TBL] [Abstract][Full Text] [Related]
22. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
23. Brain metastasis in breast cancer: a comprehensive literature review.
Rostami R; Mittal S; Rostami P; Tavassoli F; Jabbari B
J Neurooncol; 2016 May; 127(3):407-14. PubMed ID: 26909695
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer stem cells: Multiple capacities in tumor metastasis.
Geng SQ; Alexandrou AT; Li JJ
Cancer Lett; 2014 Jul; 349(1):1-7. PubMed ID: 24727284
[TBL] [Abstract][Full Text] [Related]
25. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
26. Impact of breast cancer subtypes and patterns of metastasis on outcome.
Kast K; Link T; Friedrich K; Petzold A; Niedostatek A; Schoffer O; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Breast Cancer Res Treat; 2015 Apr; 150(3):621-9. PubMed ID: 25783184
[TBL] [Abstract][Full Text] [Related]
27. A solitary brain metastasis as the only site of recurrence of HR positive, HER2 negative breast cancer: a case report and review of the literature.
Patel SH; Saito YD; Li Z; Ramaswamy B; Stiff A; Kassem M; Wesolowski R
J Med Case Rep; 2021 Jan; 15(1):4. PubMed ID: 33407851
[TBL] [Abstract][Full Text] [Related]
28. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
30. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
31. microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy.
Kanchan RK; Siddiqui JA; Mahapatra S; Batra SK; Nasser MW
Mol Cancer; 2020 Feb; 19(1):29. PubMed ID: 32059676
[TBL] [Abstract][Full Text] [Related]
32. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
Peng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
[TBL] [Abstract][Full Text] [Related]
33. ER
Arciero CA; Guo Y; Jiang R; Behera M; O'Regan R; Peng L; Li X
Clin Breast Cancer; 2019 Aug; 19(4):236-245. PubMed ID: 30846407
[TBL] [Abstract][Full Text] [Related]
34. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.
Hurvitz SA; O'Shaughnessy J; Mason G; Yardley DA; Jahanzeb M; Brufsky A; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Chu L; Li H; Antao V; Cobleigh M
Clin Cancer Res; 2019 Apr; 25(8):2433-2441. PubMed ID: 30593513
[TBL] [Abstract][Full Text] [Related]
35. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
Fan Y; Wang Y; He L; Imani S; Wen Q
ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
[TBL] [Abstract][Full Text] [Related]
36. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
Hohensee I; Lamszus K; Riethdorf S; Meyer-Staeckling S; Glatzel M; Matschke J; Witzel I; Westphal M; Brandt B; Müller V; Pantel K; Wikman H
Am J Pathol; 2013 Jul; 183(1):83-95. PubMed ID: 23665199
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer brain metastasis: Current evidence and future directions.
Sun H; Xu J; Dai S; Ma Y; Sun T
Cancer Med; 2023 Jan; 12(2):1007-1024. PubMed ID: 35822637
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.
Sihto H; Lundin J; Lundin M; Lehtimäki T; Ristimäki A; Holli K; Sailas L; Kataja V; Turpeenniemi-Hujanen T; Isola J; Heikkilä P; Joensuu H
Breast Cancer Res; 2011 Sep; 13(5):R87. PubMed ID: 21914172
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer.
Hines SL; Vallow LA; Tan WW; McNeil RB; Perez EA; Jain A
Ann Oncol; 2008 Sep; 19(9):1561-5. PubMed ID: 18534964
[TBL] [Abstract][Full Text] [Related]
40. An Insight into Molecular Targets of Breast Cancer Brain Metastasis.
Kaleem M; Dalhat MH; Azmi L; Asar TO; Ahmad W; Alghanmi M; Almostadi A; Zughaibi TA; Tabrez S
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
